TriLink BioTechnologies’ CleanCap® mRNA Capping Technology

TriLink BioTechnologies‘ CleanCap® is a groundbreaking advancement in mRNA synthesis, providing a highly efficient, co-transcriptional capping method that simplifies manufacturing while enhancing mRNA stability and translation efficiency.

1. Key Features & Benefits

• High Capping Efficiency: Achieves over 95% capping efficiency, ensuring optimal translation.
• Cap 1 Structure: Produces a natural Cap 1 structure, reducing immunogenicity and increasing mRNA stability.
• One-Pot Capping Process: Streamlines production by integrating the capping step during transcription, reducing costs and manufacturing time.
• Proven Large-Scale Use: Incorporated into over 3 billion doses of mRNA-based COVID-19 vaccines.

2. Industry Adoption & Applications

• mRNA Vaccines: Used in major mRNA vaccine platforms, including those developed for COVID-19, influenza, and personalized cancer therapies.
• mRNA Therapeutics: Applied in gene therapy, protein replacement therapy, and immunotherapies.
• Partnerships: In April 2024, TriLink signed a non-exclusive license and supply agreement with Lonza, expanding access to CleanCap® for mRNA drug development.

3. Why CleanCap® Matters

• Faster Development Timelines: Reduces the complexity of traditional enzymatic capping methods.
• Cost-Effective Scaling: Streamlined synthesis lowers production costs for large-scale mRNA manufacturing.
• Enhanced Therapeutic Performance: Improved mRNA stability leads to higher protein expression and better patient outcomes.

For biotech professionals, CleanCap® represents a critical innovation in mRNA technology, helping drive the future of RNA-based medicine.